Does Recombinant Human Erythropoietin Affect Plasma Lipids in Hemodialysis Patients?

Nephron

Volumn 74, Issue 4, 1996, Pages 731-732

  Cengiz, Kuddusi ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM ION; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL;

ANEMIA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; ENDOCRINE FUNCTION; ENZYME ACTIVITY; FOOD INTAKE; HEMATOCRIT; HEMODIALYSIS; HUMAN; LETTER; LIPID BLOOD LEVEL; LONG TERM CARE; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; TISSUE OXYGENATION; TRIACYLGLYCEROL BLOOD LEVEL; WELLBEING;

ERYTHROPOIETIN, RECOMBINANT; HUMANS; LIPIDS; RENAL DIALYSIS;

EID: 0029958419     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189484     Document Type: Article

References (5)

1. Prata MM. Sausa FT. Baibas JM. Rodrigues MC: Blood lipids in hemodialysis patients treated with erythropoietin (letter). Nephrol Dial Transplant 1990; 15:47.
2. Casati S. Passerini P. Campisc MR, Graziani G, Cesane B. Perisic M, Ponticelli C: Benefits and risk of protracted treatment with human recombinant erythropoietin in patients having hemodialysis. BrMed J 1987:295:1017-1020.
3. Brenner BM. Rector FC: Organ System Altera-tionsand Response to Hemodialysis: Lipid Abnormalities. The Kidney. Philadelphia, Saunders, 1991, vol 2. p 22-38.
4. Mat O, Stolear JC. Georges B: Blood lipid profile in hemodialysis patients treated with erythropoietin (letter). Nephron 1992:60:236-237.
5. Viron B. Donsimoni R. Michel C, Al Khayat R, Migron F: Effect of recombinant human erythropoietin on nutritional status and plasma lipids in uremic patients (letter). Nephron 1992; 60:249.